Knowledge & News

Life Sciences Report 2013

Published April 2013

Marks & Clerk's 2013 Life Sciences Report offers expert insight, backed by industry opinion, on the changing IP landscape facing the life sciences industry. In particular, it explores the impact of the America Invents Act and the European Unitary Patent and the Unified Patent Court, the issues faced by the sector in getting its therapies to patients (specifically those associated with biosimilars, SPCs and personalised medicine, including stem cell research), and the increasing importance of Asia.

Foreword by Dr Scott Alban, Vice President of Global Intellectual Property at AstraZeneca.

Authors

Mike Gilbert

Mike Gilbert Partner London (UK) Solicitor (UK)

Michael Lin

Michael Lin Partner Hong Kong (China) Beijing (China) Ohio Attorney, US Patent Attorney

Gianfranco Matteucci

Gianfranco Matteucci Partner Singapore Registered (SG), Italian Patent and European Patent, Italian and European Trade Mark Attorney

Thomas Prock

Thomas Prock Partner London (UK) Chartered (UK), German and European Patent Attorney

Gareth Williams

Gareth Williams Partner Cambridge (UK) Chartered (UK) and European Patent Attorney

Subscribe image

You may also be interested in...

.
Do I need to protect my IP?
Article

Do I need to protect my IP?

Patent, trade marks and other rights that protect revenue streams and add business value

.
Business Intelligence Q1 2020<BR/>Q1 2020
Newsletters

Business Intelligence Q1 2020
Q1 2020

POSTED 27 February 2020

Find the right person

Find the office that suits you

Click here to view our offices

>